Kornimate/medical-research-clean huggingface dataset:
enteral nutrition in cancer patient

Conditions: Malnutrition; Cancer; Pediatric

Summary: context and objective: tumor and its therapy have adverse effects on the nutritional status of cancer patients, leading to nutritional support. the aim was to study enteral nutrition indications, as well as its compliance and the impact on nutritional status. design and setting: clinical trial, iop, unifesp-epm. methods: patients older than 1 year followed during anticancer therapy were included from january 2002 to january 2004. they received industrialized oral supplementation - nutren 1.0 or jr (ios) and were followed on a weekly basis and reevaluated on weeks 3, 8 and 12: at these times, if inadequate outcome was observed, tube feeding with the same supplement (tfr) was indicated.


Eligibility criteria:
inclusion criteria: * were chemotherapy, age above one year and malnutrition. a z-score of weight for height (zw/h) \< -1.0 to -2.0 in children26 and ≥ 5th to \< 15th of body mass index (bmi) in adolescents27 were considered as mild malnutrition; and a zw/h \< -2.0 in children and \< 5th of bmi in adolescents as severe, respectively.28 in adults, the world health organization (who)29 cut-off values were applied: \< 18.5 mild and \< 17 severe malnutrition. exclusion criteria: * were corticosteroid or hormonal therapy, swallowing abnormalities, parenteral or tube feeding therapy, palliative care and presence of non cancer-related diseases.

Keywords: nutritional support. cancer. malnutrition. child. adolescent
positional therapy after stroke

Conditions: Sleep Apnea; Stroke

Summary: stroke is the leading cause of adult disability and the third leading cause of death in the united states. unfortunately, there are few therapies that have been proven to improve stroke outcome. sleep apnea is an emerging stroke risk factor and has a well established association with higher mortality and poor functional outcome following stroke. over half of acute stroke patients have sleep apnea, suggesting that it may be a important target for therapy. attenuation of sleep apnea severity may result in improved stroke outcomes. however, the standard treatment for sleep apnea is not well-tolerated among stroke patients. an alternative treatment is avoidance of supine sleep. supine sleep is very common in acute stroke patients, and therefore this treatment may have particular relevance to the stroke population. the proposed study will be conducted in two phases. the first phase is a randomized, crossover design in which acute stroke patients will be given positional treatment (to avoid supine sleep) on one night during their stroke hospitalization. this will be compared with another night of sleeping without positional therapy. the order of treatments (standard vs positional therapy) will be random. the first phase will demonstrate the proof of concept: that stroke patients given positional therapy to avoid supine sleep will (1) sleep less on their backs, and (2) will have improved sleep apnea parameters with positional therapy. in the second phase, those identified to have sleep apnea will be randomized to receive positional therapy at home for three months, or standard therapy. this second phase will demonstrate the adherence/feasibility of three months of positional therapy, and will allow us to estimate effect size based on a functional outcome measure. the data obtained from this pilot clinical trial are essential to plan a large efficacy study.


Eligibility criteria:
inclusion criteria: * age 18 or older * probable ischemic stroke within prior 14 days exclusion criteria: * any medical condition precluding the avoidance of supine posture or dictating the need for a particular position. * current use of cpap (or other pap), mechanical ventilation, or supplemental oxygen.
markers in follicular fluid and in embryo culture medium as a marker of oocyte and embryo quality

Conditions: Infertility/Sterility

Summary: assessment of the quality of follicular fluid and early embryo via chemical markers.

the selectin of an embryo for transfer is currently based on detailed morphological assessment and scoring system. morhpokinetics introduced recently to ivf laboratories can define annotations and provide an algorithm for optimal cleavage rates and embryonic development. however more data and validations are requested when it comes to choosing the best single embryo from a cohort of available similarly graded embryos. consequently, non-invasive quantitative methods for embryo selection prior to transfer have been sought. in the current study metabolic profile of follicular fluid and the embryos produced in ivf procedure will be assessed

Eligibility criteria:
inclusion criteria: * patients undergoing ivf procedures at carmel medical center and are able to sign an informed consent form. * female patients age 18-45 exclusion criteria: * women with any malignancy * patient's request to be withdrawn from the study.
efficacy of end-effector robot-assisted gait training in subacute stroke patients

Conditions: Severe Stroke; Acute Stroke; Mild Stroke; Central Nervous System Diseases; Cerebrovascular Disease; Brain Diseases; Cardiovascular Diseases; Gait, Hemiplegic

Summary: to date, no studies seems to compare conventional gait rehabilitation program with end-effector ragt in subacute stroke patients by analysing the variations of gait kinematics beyond clinical multi prospective outcomes. the aim of this pilot study is to evaluate the efficacy of end-effector ragt in subacute stroke patients in terms of clinical outcomes and gait kinematics, comparing them with conventional gait rehabilitation program.

to evaluate the efficacy of end-effector ragt in subacute stroke patients in terms of clinical outcomes and gait kinematics, comparing them with conventional gait rehabilitation program, patients following first ever stroke in sub-acute phase will be recruited and assessed both clinically and instrumentally (gait analysis) at baseline (t0) and at the end of training program (t1). the patients will be divided into 2 groups and will conduct two different types of gait training: one group will be recruited by irccs san raffaele pisana of rome and will perform, in addition to conventional therapy, gait training using an end-effector robotic device for ragt(robotic group, rg); and another group will be recruited by the don carlo gnocchi foundation onlus of rome, and will perform conventional gait rehabilitation program(conventional group, cg).

Eligibility criteria:
inclusion criteria: * first cerebral stroke * 2 weeks up to 6 months post the acute event (subacute patients) * age between 18-80 years * ability to fit into the end-effector footplates * no significant limitation of joint range of motion * ability to tolerate upright standing for 60 seconds * ability to walk unassisted or with little assistance * ability to give written consent * compliance with the study procedures exclusion criteria: * contractures of the hip, knee, or ankle joints that might limit the range of motion during gait * medical issue that precludes full weight bearing and ambulation (e.g. orthopaedic injuries, pain, severe osteoporosis, or severe spasticity) * cognitive and/or communicative disability (e.g. due to brain injury): inability to understand the instructions required for the study * cardiac pathologies, anxiety or psychosis that might interfere with the use of the equipment or testing written informed consent was obtained from each subject.

Keywords: stroke robot hemiparesis gait training rehabilitation functional recovery robot-assisted gait training
study of efficacy and safety of secukinumab in subjects with moderate to severe chronic plaque-type psoriasis

Conditions: Plaque Psoriasis

Summary: the purpose of this study was to determine if secukinumab is effective and safe in the treatment of plaque type psoriasis


Eligibility criteria:
inclusion criteria: 1. subjects must give a written, signed and dated informed consent. 2. men or women at least 18 years of age at time of screening. 3. chronic plaque-type psoriasis present for at least 6 months and diagnosed before baseline. 4. moderate to severe psoriasis as defined at baseline by: * pasi score of 12 or greater, and * iga mod 2011 score of 3 or greater (based on a static scale of 0 - 4), and * body surface area (bsa) affected by plaque-type psoriasis of 10% or greater. 5. candidate for systemic therapy. this is defined as a subject having moderate to severe chronic plaque-type psoriasis that is inadequately controlled by * topical treatment and/or, * phototherapy and/or, * previous systemic therapy. exclusion criteria: 1. forms of psoriasis other than chronic plaque-type (e.g., pustular, erythrodermic and guttate psoriasis) at screening or baseline. 2. drug-induced psoriasis. 3. ongoing use of prohibited treatments. 4. previous exposure to secukinumab (ain457) or any other biologic drug directly targeting il-17 or the il-17 receptor. 5. use of other investigational drugs at the time of enrollment, or within 5 half-lives of enrollment, or within 30 days until the expected pharmacodynamic effect has returned to baseline, whichever is longer; or longer if required by local regulations. 6. pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hcg laboratory test.

Keywords: plaque psoriasis secukinumab skin condition skin disease itching psoriasis vulgaris immune-mediated systemic disease skin lesions scaly patches papules psoriasis
psychatric impact of miscarriage in assiut university hospital

Conditions: Miscarriage

Summary: miscarriage is basically defined as intrauterine fetal death before viability (1,2). age of viability, in egypt, sets at 26 weeks of gestation (3). incidence of miscarriage is often referred to as an iceberg where the actual size of the problem cannot be determined. more than 50% of human conceptions are lost before the missed period either before or after implantation (4). in clinically recognized pregnancies, losses decrease as pregnancy progresses from 17% - 20 % after 6 weeks to only 3% at 10 weeks gestation (4). beside the high incidence of miscarriage, it implies a high psychological morbidity to both partners with increased liability to anxiety, post stress disorder and depression(5,6). this psychological impact can be attributed not only to loss of desired child but also to the traumatic event of bleeding and pain encountered by those patients (7).

miscarriage is basically defined as intrauterine fetal death before viability (1,2). age of viability, in egypt, sets at 26 weeks of gestation (3). incidence of miscarriage is often referred to as an iceberg where the actual size of the problem cannot be determined. more than 50% of human conceptions are lost before the missed period either before or after implantation (4). in clinically recognized pregnancies, losses decrease as pregnancy progresses from 17% - 20 % after 6 weeks to only 3% at 10 weeks gestation (4). beside the high incidence of miscarriage, it implies a high psychological morbidity to both partners with increased liability to anxiety, post stress disorder and depression(5,6). this psychological impact can be attributed not only to loss of desired child but also to the traumatic event of bleeding and pain encountered by those patients (7). while the clinical management of miscarriage and its physical complications have been extensively discussed; the psychological impact of this traumatic event of loss is usually overlooked especially in developing countries (8-11). moreover, there are behind-the-scene factors that trigger or correlate to the development of psychiatric morbidities following miscarriage (12,13). factors as sociodemographic, marital satisfaction, social support, individual's coping resources, history of infertility and previous miscarriage vary across different population samples, also vary in their influence on women's psychological resilience after traumatic events as miscarriage. no previous studies addressed this topic in egyptian population.

Eligibility criteria:
inclusion criteria: * all pregnant women 18:45 years old presented by intrauterine pregnancy loss before \<= 26 weeks gestation exclusion criteria: * ectopic pregnancy or vesicular mole * previous diagnosis of psychatric disorder * unwell to give consent
open-label c1 esterase inhibitor (c1inh-nf) for the prevention of acute hereditary angioedema (hae) attacks

Conditions: Hereditary Angioedema

Summary: the study objective was to evaluate the safety and efficacy of prophylactic use of c1inh-nf for the prevention of acute hae attacks.


Eligibility criteria:
inclusion criteria: - history of at least 1 hae attack per month or any history of laryngeal edema in addition, this study was open to all subjects who: * completed participation in levp2005-1/b (nct01005888) any time after the final prophylactic therapy in part b * were enrolled but not randomized in levp2005-1/a (nct00289211) after part a was closed * were enrolled and randomized in levp2005-1/a after levp2005-1/b was closed to enrollment, any time after the 3-day telephone follow-up * were excluded from levp2005-1 for any of the following reasons: * pregnancy or lactation * age less than 6 years * narcotic addiction * presence of anti-c1 inhibitor (c1inh) autoantibodies * were not enrolled in levp2005-1 after enrollment in levp2005-1 was closed, under the following circumstances: * had a diagnosis of hae: evidence of a low c4 level plus either a low c1inh antigenic level or a low c1inh functional level, or * had a known hae-causing c1inh mutation, or * had a diagnosis of hae based on a strong family history of hae as determined by the principal investigator exclusion criteria: * history of allergic reaction to c1inh or other blood products * participated in any other investigational drug study within the past 30 days other than those sponsored by lev pharmaceuticals * received blood or a blood product in the past 60 days other than c1inh-nf

Keywords: hereditary angioedema c1 esterase inhibitor (human)
levosimendan for veno-arterial ecmo weaning

Conditions: Cardiogenic Shock; Refractory Shock

Summary: veno-arterial extracorporeal membrane oxygenation (va-ecmo) is a temporary mechanical circulatory support that has been increasingly used over the last decade to restore and maintain adequate end-organ perfusion, with data suggesting improvement in outcome for patients with refractory cardiogenic shock. nevertheless, va-ecmo weaning should be questioned every day during patient's support. indeed, studies have shown that the incidence of severe complications related to ecmo is associated with longer circulatory support duration. inotropes such as dobutamine are currently used to improve myocardial contractility during va-ecmo support with the aim to enhance left ventricular ejection, aortic valve opening and to shorten ecmo duration. however, many data suggest an increase in mortality related to predisposition to myocardial ischemia and arrythmias. levosimendan is a calcium sensitizing inotropic agent with systemic, coronary and pulmonary vasodilatory properties and specific cardioprotective effect without increasing myocardial oxygen consumption. the use of levosimendan in patients undergoing va-ecmo may therefore be of interest both to reduce the duration of mechanical support and to minimize severe complication with few data suggesting a potential benefit of levosimendan for va-ecmo weaning and survival in post-cardiotomy low cardiac output syndrome with improvement of endothelial function and hemodynamics. investigators therefore sought to investigate whether the use of levosimendan improves weaning for patients undergoing va-ecmo support for refractory cardiogenic shock hospitalized in the surgical intensive care unit (icu).


Eligibility criteria:
inclusion criteria: * age ≥18 years * all consecutive patients admitted with va-ecmo support for refractory cardiogenic shock * all consecutive patients admitted for lobectomy or wedge video-assisted thoracoscopy * levosimendan administration was left to the discretion of the attending clinician exclusion criteria: * age \< 18 years * va-ecmo duration \< 48h * va-ecmo for refractory cardiac arrest * right heart or veno-venous ecmo * va-ecmo for circulatory failure following lung transplant surgery.

Keywords: refractory cardiogenic shock levosimendan va-ecmo (veno-arterial extracorporeal membrane oxygenation)
an exploratory study to investigate the inflammatory response during a cold sore episode

Conditions: Herpes Labialis

Summary: this study will treat approximately 24 participants who experience cold sores. patches will be applied to the cold sore for up to ten days, and the symptoms will be measured during daily clinic visits using non-invasive measurement techniques.


Eligibility criteria:
participants who are susceptible to cold sores that reactivate when exposed to ultraviolet (uv) light

Keywords: cold sore
differentiating recurrent brain tumor versus radiation injury using mri

Conditions: Radiation Injury; Brain Tumor

Summary: the purpose of this study is to determine if certain mri imaging sequences (pictures) are more helpful to the physicians in determining if a brain tumor has recurred or if the person has radiation injury following their treatment.

after a patient has been treated for a brain tumor by radiation the area of the brain that has been treated changes in appearance. these changes in appearance can make it hard to determine if a brain tumor has come back at the same site or if it is radiation injury. the purpose of this study is to determine if certain mri imaging sequences (pictures) are more helpful to the physicians in determining if the tumor has come back or if it is radiation injury.

Eligibility criteria:
inclusion criteria: * patients previously treated with radiation therapy (including radiosurgery), with or without previous surgery or chemotherapy, with a new contrast enhancing lesion(s) with the size of 1 cm or more on conventional brain mri examination are eligible * patients must have a previously histological confirmed brain tumor * patients must be 18 years of age or older * patients must sign a study-specific consent form approved by the institutional review board of the university of michigan indicating prior to study entry exclusion criteria: * pregnant woman * for the purpose of this radiological study and in collecting data from the patient but not from receiving the mr spectroscopy if it is clinically indicated. * patients unable to undergo mri imaging because of non-compatible devices such as cardiac pacemakers, other implanted electronic devices, or foreign body in the eye * also patients with metallic prostheses, or ferromagnetic prostheses (e.g. pins in artificial joints and surgical pins/clips in the face or skull region), or patients with braces since these devices may cause metal artifacts which may obscure the images and result in artifacts on the mr spectroscopy. * prisoners

Keywords: recurrent tumor
assessment of labour progress by intrapartum ultrasound

Conditions: Pregnancy Related; Fever; Chorioamnionitis; Labor Complication

Summary: assessment of labor progress via digital exams is considered the standard of care in most delivery rooms. however, this method can be stressful, painful and imprecise and multiple exams increase the risk for chorioamnionitis. trans-perineal ultrasound (tpus) was found to be an objective noninvasive way to monitor labor progress. the study aim is to investigate whether, in nulliparous women, the use of tpus during labor can reduce the number of vaginal exams and the incidence of chorioamnionitis.

the prevalence of chorioamnionitis in term deliveries is 1-5% and in preterm deliveries the numbers can be as high as 25%. most infections are a result of an ascending infection of the normal vaginal flora. among risk factors are nulliparity, rupture of membranes, an extended duration of labor, multiple vaginal examinations and gbs colonization. the digital vaginal examination remains to this day the standard method for evaluating the patient's cervical status. however, this method is both highly subjective as well as painful and stressogenic for the patients. in recent years there has been great progress in the field of translabial/transperineal sonography. there have been several studies which showed that this technique could be as useful as digital examinations in helping clinicians predict the course of labor. recent studies demonstrate that using transperineal sonography can reduce the perception of pain compared with routine digital vaginal examinations. even so, there has been little evidence as to whether using perineal ultrasound may also reduce peripartum and puerperal infections and if using sonography and refraining from digital examinations affects the course and duration of labor. our objective is to evaluate whether the incidence of chorioamnionitis or fever can be decreased. this goal would hopefully be achieved by assessing the progression of labor using mostly transperineal ultrasound, thus avoiding digital vaginal examination as much as possible. the study would focus on primigravid women as they are known to be in a higher risk for infection and also other potential risk factors such as gbs carriers and prom.

Eligibility criteria:
inclusion criteria: * primigravida * gestational age ≥ 37 weeks (according to 1st trimester sonography) * single fetus •cephalic presentation exclusion criteria: o other known active infection (such as urti, uti) * women who are taking immunosuppressive therapy * women who arrived in active labor and delivered before being assessed by a physician. * women with contra-indications for vaginal birth
epinephrine inhalation aerosol usp, clinical study-b3 for assessment of pharmacokinetics

Conditions: Asthma

Summary: this study examines the pharmacokinetic profile of armstrong's proposed epinephrine inhalation aerosol usp, an hfa134a propelled metered dose inhaler (mdi) (e004), using a stable isotope deuterium-labeled epinephrine (epinephrine-d3) to differentiate the administered drug from the endogenous epinephrine, in healthy male and female adult volunteers.

the current study is designed to complement and expand the previous pk studies, api-e004-cl-b and api-e004-cl-b2, with emphasis on lower e004 dose strengths (at 90 and 100 mcg per inhalation), for a more thorough evaluation of the e004 pk profiles. safety of e004 will also be evaluated, under augmented dose conditions.

Eligibility criteria:
inclusion criteria: * generally healthy at screening; * body weight ≥ 50 kg for men and ≥ 45 kg for women; * sitting blood pressure ≤ 135/90 mmhg; * demonstrating negative hiv, hbsag and dcv-ab screen tests; * women of child-bearing potential must be non-pregnant, non-lactating, and practicing a clinically acceptable form of birth control; * properly consented * other criteria apply exclusion criteria: * a smoking history of ≥10 pack-years, or having smoked within 6 months prior to screening; * upper respiratory tract infections within 2 wk, or lower respiratory tract infection within 4 wk, prior to screening; * any current or recent respiratory conditions that might significantly affect pharmacodynamic response to the study drugs; * known intolerance or hypersensitivity to the study mdi ingredients; * having been on other investigational drug/device studies, or donated blood, in the last 30 days prior to screening; * other criteria apply

Keywords: asthma shortness of breath wheezing